Biomea Fusion (BMEA)
NASDAQ:BMEA
Top Page
Biomea Fusion
(NASDAQ:BMEA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▲(9.49% Upside)
Action:ReiteratedDate:03/27/26
The score is primarily constrained by weak financial performance (pre-revenue losses, negative free cash flow, and equity erosion despite improved 2025 burn and low debt). Technicals are mixed with only partial trend improvement, while valuation is supported by the low P/E but lacks dividend support.
Positive Factors
Low financial leverage
Very low debt levels materially reduce near-term solvency risk for a loss-making biotech. This structural balance-sheet strength gives management flexibility to fund clinical programs, negotiate partnerships, or time financings without immediate pressure from large interest or principal repayments.
Negative Factors
Pre-revenue operations
Being pre-revenue means the business remains fully dependent on external capital to fund development. Without product sales, recurring funding needs and capital-market access are structural constraints that can dilute shareholders and limit long-term autonomy if clinical timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Very low debt levels materially reduce near-term solvency risk for a loss-making biotech. This structural balance-sheet strength gives management flexibility to fund clinical programs, negotiate partnerships, or time financings without immediate pressure from large interest or principal repayments.
Read all positive factors
Biomea Fusion (BMEA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$95.44M
Dividend YieldN/A
Average Volume (3M)2.40M
Price to Earnings (P/E)4.9
Beta (1Y)1.58
Revenue GrowthN/A
EPS Growth40.22%
CountryUS
Employees79
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.06
Shares Outstanding72,299,440
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-25.67
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$6.80Price Target Upside396.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.87
Revenue Forecast (FY)N/A
Biomea Fusion Business Overview & Revenue Model
Company Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally...
How the Company Makes Money
null...
Biomea Fusion Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -79.90M | -142.32M | -124.62M | -82.94M | -41.42M |
| Net Income | -61.80M | -138.43M | -117.25M | -81.83M | -41.57M |
Balance Sheet | |||||
| Total Assets | 58.57M | 79.94M | 199.93M | 129.31M | 185.71M |
| Cash, Cash Equivalents and Short-Term Investments | 55.81M | 58.28M | 176.87M | 113.05M | 173.52M |
| Total Debt | 1.59M | 8.77M | 10.30M | 2.29M | 2.85M |
| Total Liabilities | 29.02M | 28.36M | 30.69M | 20.77M | 6.92M |
| Stockholders Equity | 29.55M | 51.57M | 169.24M | 108.54M | 178.78M |
Cash Flow | |||||
| Free Cash Flow | -70.37M | -120.26M | -99.96M | -63.45M | -38.61M |
| Operating Cash Flow | -70.37M | -119.89M | -96.59M | -62.42M | -35.44M |
| Investing Cash Flow | 0.00 | -362.00K | -2.22M | 27.34M | -33.35M |
| Financing Cash Flow | 67.90M | 1.67M | 163.80M | 1.24M | 153.19M |
Biomea Fusion Technical Analysis
Positive
1.37
Price Trends
1.29
Positive
1.29
Positive
1.56
Negative
Market Momentum
-0.02
Negative
52.59
Neutral
64.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Positive. The current price of 1.37 is above the 20-day moving average (MA) of 1.30, above the 50-day MA of 1.29, and below the 200-day MA of 1.56, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 52.59 is Neutral, neither overbought nor oversold. The STOCH value of 64.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BMEA.
Biomea Fusion Risk Analysis
Biomea Fusion disclosed 91 risk factors in its most recent earnings report. Biomea Fusion reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biomea Fusion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $303.31M | -6.90 | -23.98% | ― | 946.61% | -11.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $95.44M | 4.86 | -209.00% | ― | ― | 40.22% | |
48 Neutral | $130.17M | 811.87 | -0.04% | ― | -33.41% | 81.19% | |
46 Neutral | $40.65M | -2.19 | -49.42% | ― | ― | -9.42% | |
46 Neutral | $93.66M | -1.64 | -26.04% | ― | 13.77% | -4.76% | |
45 Neutral | $111.24M | -9.60 | -353.36% | ― | -10.36% | 42.36% |
* Healthcare Sector Average
BMEA
Biomea Fusion
1.32
-0.98
-42.61%
AGEN
Agenus
3.39
1.79
111.87%
INO
Inovio Pharmaceuticals
1.61
-0.12
-6.94%
ATOS
Atossa Therapeutics
4.72
-5.72
-54.80%
OVID
Ovid Therapeutics
2.30
1.95
557.14%
SEER
Seer
1.66
-0.08
-4.60%
Biomea Fusion Corporate Events
Business Operations and StrategyProduct-Related Announcements
Biomea Fusion Updates Corporate Presentation on Metabolic Pipeline
Positive
Feb 25, 2026
On February 25, 2026, Biomea Fusion updated and published a new corporate presentation for investors and analysts, detailing the status of its metabolic disease pipeline and making the materials available on its website. The refreshed deck undersc...
Business Operations and StrategyProduct-Related Announcements
Biomea Fusion Highlights Diabetes Pipeline at JPM Conference
Positive
Jan 14, 2026
On January 14, 2026, Biomea Fusion presented updated data on its diabetes and obesity pipeline at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and concurrently refreshed its corporate presentation for ongoing use with investo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.